3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Esophageal Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
780
Fluorouracil
638
Capecitabine
575
Gemcitabine
478
Leucovorin
459
Bevacizumab
445
Irinotecan
444
Cisplatin
338
Radiotherapy
283
Cetuximab
252
Paclitaxel
180
S 1 (combination)
176
pembrolizumab
173
Docetaxel
156
Drug Therapy
147
Nivolumab
146
sintilimab
143
tislelizumab
131
apatinib
131
130-nm albumin-bound paclitaxel
128
Folfox protocol
121
durvalumab
119
Albumin-Bound Paclitaxel
117
camrelizumab
107
lenvatinib
106
Panitumumab
106
regorafenib
102
Surgical Procedures, Operative
102
Sorafenib
99
Radiation
88
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
matuzumab
×
Gastrointestinal
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts